Sandro Vivona’s Post

We’ve added 13 new clinically-aligned pretreated PDX models! Clinically-aligned pretreated PDX models represent patients who received multiple lines of treatment. View our factsheet to view the patient treatment histories which include several targeted therapies like Immune Checkpoint Inhibitors and different modalities like Antibody Drug Conjugates. Learn more https://bit.ly/4aQdDtT #OncologyResearch #DrugDevelopment

Antibody Drug Conjugates: What Are Antibodies? - OncTalk Lung 2023 https://lnkd.in/d5J-5C7m via @YouTube In this video, Dr. Lyudmila Bazhenova, MD gives a quick overview of what antibodies are, and how they kill cancer cells. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://lnkd.in/ekmZ-Pe. #lungcancer #nsclc

Discover Our Novel PTK7 BsADC Assets: PTK7 x EGFR BsADC (BCG017) Our PTK7 x EGFR BsADC (BCG017) targets tumor-associated antigens highly co-expressed in esophageal carcinoma, NSCLC, and TNBC. This asset has shown superior anti-tumor efficacy compared to parental monoclonal ADCs and benchmark ADCs in vivo. Development Stage: PCC. Partner with us to leverage our RenLite® Platform, enabling the rapid development of bispecific antibody and bispecific antibody-drug-conjugate (ADC) therapies for your pipeline. #Biocytogen #PTK7 #bsADC #BispecificAntibody #Immunotherapy #BiotechInnovation #DrugDiscovery #HealthcareInnovation

If you need help taking your research to the clinic, let me help you! Our customized gene editing capabilities and pharmacology services, coupled with our partnership will accelerate your research to the clinic. Reach out to learn more! #preclinical #geneediting #crispercas9 #pharmacology #cancer #mousemodels #nuerology #cardiovascular

If you are at #sitc2023 this year, join me at poster #468 to hear all about our anti-PD1 inhibitor: LOQTORZI, the first and only approved treatment for nasopharyngeal carcinoma! If you are more interested in learning about our first-in-class anti-IL-27 antibody (Casdozokitug) or CHS-114 (formerly SRF114) an ADCC-enhanced anti-CCR8 antibody that are currently being evaluated in clinical trials, stop by at posters #1351 and #1354 respectively.

Bispecific antibodies (bsAbs) offer novel therapeutic mechanisms, distinct from both monotherapies and combination therapies. They offer conditional activation or precise targeting of the tumor microenvironment to mitigate systemic toxicity. Additionally, bispecific antibodies offer dual blockade abilities, effectively addressing drug resistance concerns. By the end of 2023, 14 bsAbs received approval, with 11 indicated for cancer and 3 for non-oncology indications. Check out our 4-1BB x CD40 fully human bsAb (BCG021)(https://lnkd.in/epzEgCtx) and EGFR x CD70 fully human bsAb (BCG020) (https://lnkd.in/eJxhm-Fr). #antibodylibrary #renbiologics #drugdiscovery #TumorResearch #antibodytherapeutics #immunotherapy #cancerresearch #cancertherapy #Bispecific #bsab

Today marks a milestone in our mission to transform cancer treatment through anchored immunotherapy: The U.S. Food and Drug Administration (FDA) and Health Canada have cleared our Investigational New Drug (IND) application for ANK-101, enabling us to enroll patients in our Phase I dose-escalation study evaluating the safety and tolerability of ANK-101 in solid tumors. By anchoring to and being retained at the tumor site, ANK-101 has the ability to avoid hallmark challenges of both systemic and intratumoral therapies, effectively training the body to potently destroy cancer cells. We look forward to bringing this new approach to those who need it most.   Read more: https://lnkd.in/euVHR4bT #biotech #INDapproval

#DidYouKnow: We are leveraging TEM8 – a protein with low expression on healthy cells and high expression on cancer-associated cells – as a lamppost to guide the delivery of cancer-fighting therapies into the tumor microenvironment. We believe TEM8-directed therapeutic antibodies have the potential to be used across multiple modalities, and our initial focus is TEM8-directed antibody drug conjugates (ADCs). Learn more: https://lnkd.in/eSb8E99m #AntibodyDrugConjugates #ADC #TumorMicroenvironment #CancerResearch #JPM24

We proudly presented deeper insights into the novel target engagement, amyloid plaque reduction and ARIA findings from our Phase 1 trial of ACU193, our Aβ oligomer-directed, next-generation antibody therapy during a late-breaking symposium at #CTAD23. These results further support proof-of-mechanism for ACU193, the first clinical-stage antibody treatment that selectively targets Aβ oligomers, a highly toxic form of amyloid beta and an early and persistent driver of Alzheimer’s disease Learn more about the expanded analyses: https://lnkd.in/gG63EYCV

This new article with contributions from Hartmut Koeppen in #GenentechResearchPathology has identified loss of CD20 as a previously unknown mechanism of resistant to the CD20xCD3 bispecific antibody #mosunetuzumab. This reinforces the utility of readily-available #IHC staining for CD20 as a tool to inform clinical decisions.#genentech #lymphoma